Leukogene Boosts Leadership with Dr. Gupta

Leukogene Therapeutics Inc., a biotech company focused on developing immunotherapies for challenging cancers, has announced Dr. Sandeep Gupta as its new CEO. Dr. Gupta brings over 25 years of pharma experience, including founding Asana BioSciences, where he led the discovery and clinical development of novel drug candidates and secured successful financing and licensing deals.

Leukogene's leadership, including Chairman Dr. Lawrence Olanoff, expressed confidence in Dr. Gupta’s expertise, particularly in oncology and immunology. Co-founders Dr. Nathan Dolloff and Dr. Frank Marcoux highlighted his role in advancing the company’s proprietary MT2™ immunotherapy platform targeting "cold" tumors.

Dr. Gupta, previously a leader at Kashiv BioSciences, Endo Health Solutions, and Forest Laboratories, emphasized his excitement to further Leukogene’s mission of delivering transformative cancer treatments. With a robust academic and professional background, he aims to leverage the company's innovative approach to mobilize immune responses against difficult-to-treat cancers.